Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
Total Valuation
Adverum Biotechnologies has a market cap or net worth of $46.27M. The enterprise value is ―.
Market Cap$46.27M
Enterprise Value―
Share Statistics
Adverum Biotechnologies has 20,890,575 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,890,575
Owned by Insiders22.11%
Owned by Institutions0.40%
Financial Efficiency
Adverum Biotechnologies’s return on equity (ROE) is -1.40 and return on invested capital (ROIC) is -77.51%.
Return on Equity (ROE)-1.40
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-77.51%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee23.23K
Profits Per Employee-755.90K
Employee Count155
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Adverum Biotechnologies is -0.65. Adverum Biotechnologies’s PEG ratio is -0.04.
PE Ratio-0.65
PS Ratio0.00
PB Ratio0.67
Price to Fair Value0.91
Price to FCF-1.11
Price to Operating Cash Flow-1.12
PEG Ratio-0.04
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of 3.60M and earned -117.17M in profits. Earnings per share was -11.62.
Revenue3.60M
Gross Profit-2.04M
Operating Income-123.99M
Pretax Income-118.24M
Net Income-117.17M
EBITDA-118.35M
Earnings Per Share (EPS)-11.62
Cash Flow
In the last 12 months, operating cash flow was -85.62M and capital expenditures -519.00K, giving a free cash flow of -86.14M billion.
Operating Cash Flow-85.62M
Free Cash Flow-86.14M
Free Cash Flow per Share-4.12
Dividends & Yields
Adverum Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-75.03%
50-Day Moving Average3.81
200-Day Moving Average5.58
Relative Strength Index (RSI)28.66
Average Volume (3m)450.90K
Important Dates
Adverum Biotechnologies upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Adverum Biotechnologies as a current ratio of 4.13, with Debt / Equity ratio of 50.84%
Current Ratio4.13
Quick Ratio4.13
Debt to Market Cap0.00
Net Debt to EBITDA>-0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Adverum Biotechnologies has paid -1.08M in taxes.
Income Tax-1.08M
Effective Tax Rate<0.01
Enterprise Valuation
Adverum Biotechnologies EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.83.
EV to Sales21.10
EV to EBITDA-0.64
EV to Free Cash Flow-0.83
EV to Operating Cash Flow-0.84
Balance Sheet
Adverum Biotechnologies has $153.24M in cash and marketable securities with $73.26M in debt, giving a net cash position of -$79.98M billion.
Cash & Marketable Securities$153.24M
Total Debt$73.26M
Net Cash-$79.98M
Net Cash Per Share-$3.83
Tangible Book Value Per Share$8.28
Margins
Gross margin is 248.15%, with operating margin of -3444.19%, and net profit margin of -3254.58%.
Gross Margin248.15%
Operating Margin-3444.19%
Pretax Margin-3284.53%
Net Profit Margin-3254.58%
EBITDA Margin-3287.42%
EBIT Margin-3444.19%
Analyst Forecast
The average price target for Adverum Biotechnologies is $17.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.50
Price Target Upside749.51% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-72.22%
EPS Growth Forecast51.40%